American Dental Association following a small but growing number of reports linking bisphosphonate drugs like Fosamax, Boniva, and Actonel to incidences of osteonecrosis of the jaw (dead bone tissue), believes that dentists should discuss ONJ risks with dental patients who are taking Fosamax, Boniva, and Actonel when performing tooth extraction or doing implants.

A failure to do so could constitute Dental Malpractice. Dentists and their patients should carefully consider these procedures and discuss alternative dental therapies.

Posted by Michael Monheit at 02:53 PM | Permalink

Researchers from the H. Lee Moffitt Cancer Center and Loyola University have published suggestions for the management of adverse effects associated with intravenous bisphosphonate therapy. The details of this report appeared in the June 2006 issue of the Annals of Oncology. Aredia and Zometa intravenous bisphosphonates are widely used to prevent or treat bone loss in patients with cancer and to treat cancer related hypercalcemia. The article cites that about 2 percent of patients have serious complications after receiving these intravenous drugs. The article goes on to state the list of complications and how if any may be prevented. (Cancer Consultants)

Posted by Michael Monheit at 05:32 AM | Permalink